Evidence map›Paper›PMID 40455140›Full record

ArticleImmunologic research2025

T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer.

Zirui Xue, Zhaoming Wang, Dan Liu, Bosen Li, Zhaodong Sun, Junjie Zhao, Haojie Li, Xuefei Wang, Yihong Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zirui Xue *Department of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Zhaoming Wang *Department of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Dan Liu *Department of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Bosen LiDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Zhaodong SunDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Junjie ZhaoDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Haojie LiDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. li.haojie@zs-hospital.sh.cn.
Xuefei WangDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. wang.xuefei@zs-hospital.sh.cn.
Yihong SunDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. sun.yihong@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-HER2 monoclonal antibody (mAb) is the standard first-line therapy for advanced HER2

Indexed as

Antibody-Dependent Cell CytotoxicityAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesStomach NeoplasmsT-LymphocytesAgedAntibodies, BispecificAntibodies, MonoclonalCell Line, TumorFemaleHumansKiller Cells, NaturalLymphocyte ActivationMaleMiddle AgedAntibodies, BispecificAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesADCCAnti-HER2Bispecific antibodyNK cell

Identifiers

PMID40455140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.